Fate Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The unaudited filing covers a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. It has no product sales; reported revenue is from collaborations and grants.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Collaboration revenue | $1.9 million | $59.0 million |
| Research and development expense | $32.1 million | $65.6 million |
| General and administrative expense | $20.9 million | $21.9 million |
| Operating loss | $51.1 million | $28.6 million |
| Net loss | $48.0 million | $18.9 million |
| Net loss per share, basic and diluted | $0.47 | $0.19 |
| Net cash used in operations | $33.4 million | $28.9 million |
- At March 31, 2024, cash and cash equivalents were $121.3 million, short-term investments $262.2 million, and long-term investments $7.6 million; together, cash and investments were approximately $391.1 million. Current assets were $394.4 million and current liabilities $45.4 million.
- The company reported no borrowings or debt balance. Operating lease liabilities totaled $102.1 million, with $159.3 million in undiscounted future lease payments.
- Management said available cash, cash equivalents, and investments were expected to fund projected operating requirements for at least the next 12 months. The company cautioned that development costs, timing, and funding needs are uncertain.
- There is no meaningful product gross margin to report because the company has not generated therapeutic product sales. The filing does not provide a clear operating-margin measure.
Changes versus the prior period
- Revenue declined $57.1 million, primarily because Janssen collaboration revenue recognized in Q1 2023 did not recur after Janssen’s agreement termination took effect in April 2023. Q1 2023 included $52.3 million from Janssen; Q1 2024 revenue was from Ono.
- R&D expense fell $33.5 million, principally due to lower employee compensation following the 2023 restructuring, lower consultant and clinical-trial costs, and lower licensing fees. Despite lower expenses, the loss from operations and net loss increased because the revenue decline was larger.
- Operating cash use increased by $4.5 million year over year. The March 2024 public offering and concurrent pre-funded warrant placement provided substantial financing cash.
- Cash and investments increased from approximately $316.2 million at December 31, 2023 to $391.1 million at March 31, 2024. Common shares outstanding rose from 98.6 million to 113.8 million during the quarter.
Outlook, material developments, and risks
- No specific revenue, earnings, or clinical-development guidance was provided. The company expects significant losses and expenses to continue and does not expect meaningful product revenue for years, if ever, absent successful development and regulatory approval.
- In March, the company sold 14.5 million common shares at $5.50 per share and issued pre-funded warrants for 3.6 million shares at $5.499 per warrant. Cash-flow reporting shows net proceeds of $75.2 million from the offering and $20.0 million from the warrant placement. The company said approximately $220 million remained available under its shelf registration statement, including its $100 million at-the-market program.
- In February, CIRM approved a $7.9 million grant to support the Phase 1 FT819 study in systemic lupus erythematosus; the award agreement was finalized in April 2024 and payments are subject to co-funding and development milestones. In May, the company achieved an Ono development milestone entitling it to a $5.0 million payment; both are subsequent events relative to the quarter.
- Ono committed research funding through September 2024. Its option for Candidate 3 was scheduled to expire by September 30, 2024, unless the specified milestone occurred earlier; Ono may defer its decision to no later than June 2026 by paying an extension fee. The collaboration provides potential future milestone payments and royalties, but these are contingent.
- Key risks include early-stage and uncertain clinical development, safety and regulatory hurdles for novel iPSC and gene-edited therapies, manufacturing scale-up and supply constraints, dependence on collaborators and third-party suppliers, competition, and the possibility of needing additional capital. Future equity financing could further dilute shareholders.
- Legal matters include a securities class action and a related derivative action (the latter stayed pending the class-action motion to dismiss), ongoing state-court litigation involving Shoreline and a former scientific advisor, and an appeal of a federal patent-infringement judgment in Shoreline’s favor. Outcomes and potential financial impacts are uncertain.
- The company recorded $1.4 million of Q1 expense from remeasuring stock-price appreciation milestones owed under its MSKCC license; the related liability was $2.7 million at quarter-end. The remaining potential milestone payments are contingent on the stock price, up to $75 million in total under the agreement.
Investor facts to verify
- Confirm the timing and amount of operating cash burn against management’s stated minimum 12-month liquidity outlook, including the impact of clinical and manufacturing spending.
- Track clinical progress, enrollment, safety findings, and manufacturing readiness for the company’s active programs, particularly FT819 in lupus.
- Monitor Ono’s funding, Candidate 3 option decision, and receipt of the $5.0 million milestone payment; verify grant disbursement conditions for the CIRM award.
- Assess dilution from the March offering and outstanding pre-funded warrants, as well as potential future issuance under the shelf and at-the-market program.
- Follow the Shoreline and securities-related litigation, and the valuation and potential payment timing of MSKCC stock-price milestones.